Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19.
Int J Biol Sci
; 17(9): 2348-2355, 2021.
Article
in English
| MEDLINE | ID: covidwho-1285527
ABSTRACT
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explored the interaction networks of kinase and COVID-19 crosstalk, and identified phosphoinositide 3-kinase (PI3K)/AKT pathway as the most important kinase signal pathway involving COVID-19. Further, we found a PI3K/AKT signal pathway inhibitor capivasertib restricted the entry of SARS-CoV-2 into cells under non-cytotoxic concentrations. Lastly, the signal axis PI3K/AKT/FYVE finger-containing phosphoinositide kinase (PIKfyve)/PtdIns(3,5)P2 was revealed to play a key role during the cellular entry of viruses including SARS-CoV-2, possibly providing potential antiviral targets. Altogether, our study suggests that the PI3K/AKT kinase inhibitor drugs may be a promising anti-SARS-CoV-2 strategy for clinical application, especially for managing cancer patients with COVID-19 in the pandemic era.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pyrimidines
/
Pyrroles
/
Proto-Oncogene Proteins c-akt
/
Virus Internalization
/
SARS-CoV-2
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
/
Randomized controlled trials
Limits:
Animals
/
Humans
Language:
English
Journal:
Int J Biol Sci
Journal subject:
Biology
Year:
2021
Document Type:
Article
Affiliation country:
Ijbs.57810
Similar
MEDLINE
...
LILACS
LIS